Hematologic malignancies rapidly increasing and unaddressed in Sub-Saharan Africa

By Ellen de Graffenreid
Hematologic malignancies rapidly increasing and unaddressed in sub-Saharan Africa
The cancer clinic at UNC Project in Lilongwe, Malawi.

(Medical Xpress) -- Sub-Saharan Africa is experiencing a growing cancer burden, and hematologic malignancies account for almost 10 percent of cancer deaths in the region.  In the United States and other resource-rich settings, patients with diseases such as non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia and multiple myeloma have benefited from treatment advances that have resulted in unprecedented rates of long-term control.

A study pre-published on-line in the March 28, 2012 issue of the journal Blood, argues that these diseases can be effectively treated in a resource-limited setting and offers a clinical service and research agenda to address the growing impact of hematologic malignancies in sub-Saharan Africa.

UNC hematology/oncology and infectious disease fellow Satish Gopal, MD, MPH, is corresponding author on the study.  He notes, “Aging, social and behavioral trends, HIV, and other endemic infections are all contributing to a rapidly increasing cancer burden in sub-Saharan Africa which has the potential to overwhelm fragmented and under-resourced health systems in this part of the world.”

has few resources to diagnose, treat and provide supportive and palliative care to patients with . What is more, available services are concentrated in major population centers in more economically advanced countries, while 63 percent of the population lives in rural areas.  The research team notes critical shortages in the availability of pathologists with expertise in these diseases, an 82 percent deficit in radiotherapy facilities (with 21 countries in the region having no operational units), limited supportive care, and extremely limited facilities for bone marrow and stem cell transplantation.  In addition, chemotherapy availability is highly restricted and cancer medicines can be difficult to administer due to the need for specialized facilities and trained personnel. Global shortages of many generic chemotherapy drugs are further challenging the region’s ability to treat cancer effectively.

Other challenges in the care of these patients include a high endemic infectious burden, as many antibacterial and antifungal drugs commonly used in developed regions are simply unavailable to support patients who are immunosuppressed from cancer treatment, HIV, malnutrition, and other factors.  The region also lacks a blood transfusion infrastructure including lack of centralized national systems for blood collection and banking.  Finally, pain management drugs are often highly-regulated or unavailable.

The research team suggests that strategies can be developed for addressing these issues, including development of conventional and new diagnostics adapted to low-resource settings, making cancer medicines affordable and integrating newer treatments, using the care and research infrastructure established to deal with HIV and other infectious diseases to study and control cancer, increasing global funding for cancer while rigorously assessing cost-effectiveness of control measures, and addressing critical health worker shortages by focusing on training efforts.

add to favorites email to friend print save as pdf

Related Stories

Anti-HIV vaginal gel promising protection in Africa, SE asia

Apr 20, 2011

A new vaginal microbicide gel and drug formulation looks promising for empowering women in developing countries to protect themselves from HIV during intercourse, without having to inform their partners, according to research ...

Scientists find new drug target for hard-to-treat leukaemia

Mar 30, 2012

(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Recommended for you

Discovery could lead to new cancer treatment

17 hours ago

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

23 hours ago

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments